Goldman Sachs Casts Doubt on MoonLake's Sonelokimab, Despite Bullish Pipeline Data and Higher Price Target
In a nuanced move that highlights the complex calculus of biotech investing, Goldman Sachs has increased its price target on clinical-stage biopharma MoonLake Immunotherapeutics (NASDAQ: MLTX) while reiterating a cautious stance on the company's future.
The investment bank lifted its target to $11 from $10, as reported by TheFly on February 26, following MoonLake's fourth-quarter and full-year results. The company's financial runway appears solid, with cash reserves expected to fund operations into late 2027. However, Goldman's central reservation remains unchanged: significant skepticism regarding the likelihood of regulatory approval for MoonLake's lead candidate, sonelokimab (SLK).
This skepticism persists despite a recent pipeline update that showcased compelling clinical data. On February 22, MoonLake disclosed topline results from its Phase 2 S-OLARIS study evaluating SLK in patients with axial spondyloarthritis (axSpA). The data reported that 81% of treated patients achieved a stringent ASAS40 response at Week 12, with over 80% showing clinically important improvement. Advanced imaging and biomarker analyses supported these findings, demonstrating reduced inflammation and osteoblast activity with a safety profile consistent with prior studies.
"The Phase 2 data is undoubtedly positive from a scientific perspective," said Dr. Anya Sharma, a rheumatologist at Boston Medical Center. "It shows robust efficacy in a difficult-to-treat condition. The real question for investors is translational: can this data package convince regulators, and how will it differentiate itself in a crowded immunology market?"
MoonLake, which focuses on developing Nanobody-based therapies for inflammatory diseases like hidradenitis suppurativa and psoriatic arthritis, plans to advance SLK into further clinical development. The company's inclusion on several analyst lists of promising small-cap stocks underscores the high-risk, high-reward nature of its story.
"Goldman's move is classic Wall Street—giving with one hand and taking with the other," commented Mark Reynolds, a portfolio manager at a healthcare-focused hedge fund. "The raised target acknowledges the operational progress and strong data. The maintained 'Sell' is a stark reminder that regulatory approval is the ultimate gatekeeper, not just good science."
A more critical view came from Lisa Chen, a patient advocate for chronic inflammatory conditions. "It's frustrating to see promising data met with such institutional pessimism," Chen said sharply. "Patients waiting for new options don't care about price targets. They see effective suppression of disease activity and want to know why the path to approval isn't being treated with more urgency. This 'sell' rating feels detached from the human impact."
As the biotech sector navigates a challenging funding environment, MoonLake's journey with SLK will serve as a key case study in how clinical promise is weighed against regulatory and commercial hurdles by the investment community.